Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

NCT01010061

CompletedPhase 3

Sponsor: Hoffmann-La Roche

Conditions: Lymphocytic Leukemia, Chronic

Interventions: obinutuzumab, rituximab, chlorambucil

Countries: United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Croatia

This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL). Patients will be randomized 2:2:1 to receive a maximum of six 28-day cycles of either RO5072759 (1000 mg intravenous (iv) infusion, on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6) plus chlorambucil (0.5 mg/kg orally, days 1 and 15 of cycles 1-6), or rituximab (iv infusion day 1, 375 mg/m\^2 cycle 1, 500 mg/m\^2 cycles 2-6) plus chlorambucil, or chlorambucil alone. Anticipated time on study treatment is \>6 months and follow-up for disease-progression and safety will be at least 5 years. In the US, this trial is sponsored/managed by Genentech.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Adults \>/=18 years
* Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL)
* Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria
* Total Cumulative Illness Rating Scale (CIRS) \> 6 and/or creatinine clearance \< 70 ml/min

Exclusion Criteria:

* Prior CLL therapy
* Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
* History of other malignancy unless the malignancy has been in remission without treatment for \>/=2 years prior to enrolment, and except for carcinoma in situ of the cervix, basal or squamous cell skin cancer, surgically treated low-grade prostate cancer, or ductal carcinoma in situ (DCIS) of the breast treated with lymphectomy alone
* Positive hepatitis serology (HBV, HCV) or positive HIV or Human T Cell Leukemia Virus (HTLV) testing
* Patients with active infection requiring systemic treatment
Locations (261)
  • San Diego, California, United States
  • Chicago, Illinois, United States
  • Baltimore, Maryland, United States
  • Green Bay, Wisconsin, United States
  • Waukesha, Wisconsin, United States
  • Buenos Aires, Argentina
  • Buenos Aires, Argentina
  • Buenos Aires, Argentina
  • Buenos Aires, Argentina
  • Buenos Aires, Argentina
  • Buenos Aires, Argentina
  • Rosario, Argentina
  • Adelaide, New South Wales, Australia
  • Gosford, New South Wales, Australia
  • Kogarah, New South Wales, Australia
  • Liverpool, New South Wales, Australia
  • St Leonards, New South Wales, Australia
  • Sydney, New South Wales, Australia
  • Greenslopes, Queensland, Australia
  • Southport, Queensland, Australia
  • Woolloongabba, Queensland, Australia
  • Kurralta Park, South Australia, Australia
  • Frankston, Victoria, Australia
  • Melbourne, Victoria, Australia
  • Graz, Austria
  • Innsbruck, Austria
  • Vienna, Austria
  • Vienna, Austria
  • Goiânia, Goiás, Brazil
  • Belo Horizonte, Minas Gerais, Brazil
  • + 231 more on CT.gov